Allergan Aesthetics (AbbVie) Acquires Soliton

Hologic Acquires Gynesonics

January 6, 2025

Medical Devices

Hologic has completed the acquisition of Gynesonics for approximately $350 million. The purchase adds the Sonata System — a minimally invasive intrauterine ultrasound-guided radiofrequency ablation platform for treating uterine fibroids — to Hologic's portfolio, expanding its capabilities in women's health surgical solutions.

Advanced Instruments Acquires Solentim

August 5, 2021

Medical Devices

Advanced Instruments has signed a definitive agreement to acquire Solentim for approximately USD 240 million, in a strategic add-on funded mainly with equity from Patricia Industries. The acquisition expands Advanced Instruments' bioprocessing instruments and consumables portfolio and combines complementary imaging, automation and single-cell cloning capabilities; Solentim is headquartered in Bournemouth, United Kingdom, and reported ~USD 17m revenue and ~USD 5m adjusted EBITDA for the 12 months to June 2021.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

Carlyle Acquires Minority Stake in Resonetics

December 3, 2021

Medical Devices

Funds managed by Carlyle have acquired a significant minority equity stake in Resonetics, valuing the specialized medical device contract manufacturer at approximately $2.25 billion. Carlyle will join existing investor GTCR as a meaningful shareholder while Sverica retains a minority position; the investment will support Resonetics’ continued organic growth, international expansion and add-on acquisition strategy.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.